Responder recipients also showed increased CD56+CD8+ T cells (CD56 being a marker of enhanced cytotoxic functions) in the peripheral blood and increased gene expression of human leukocyte antigen (HLA) Class II genes, CD74, and granzyme K (GZMK), suggesting activation of circulating and tumour-infiltrating T cells [65]. The gene discussed is NCAM1; the disease is neoplasm.